Supplementary Table S2 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

2026 Open access

Read full text
Authors: Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, Mauro Biffoni, Sara Lonardi, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo A. Ascierto, Giovanni Blandino, Giulia d’Amati, Massimo Aglietta
+34 more PierFranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Domenico Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Giuseppe Curigliano, Paolo Marchetti
DOI: 10.1158/1078-0432.31006878
Cited by: 0

Abstract

Supplementary Table S2. Matching between genomic alteration and drug proposed by MTB in ITT population.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Statistical Methods in Clinical Trials Lung Cancer Treatments and Mutations

Publication details

Publication date
6 January 2026